BAYER HLTHCARE Company Profile
✉ Email this page to a colleague
What is the competitive landscape for BAYER HLTHCARE, and when can generic versions of BAYER HLTHCARE drugs launch?
BAYER HLTHCARE has fifty-six approved drugs.
There are thirty-seven US patents protecting BAYER HLTHCARE drugs.
There are eight hundred and seven patent family members on BAYER HLTHCARE drugs in fifty-eight countries and one hundred and forty-nine supplementary protection certificates in twenty countries.
Summary for BAYER HLTHCARE
International Patents: | 807 |
US Patents: | 37 |
Tradenames: | 57 |
Ingredients: | 37 |
NDAs: | 56 |
Drugs and US Patents for BAYER HLTHCARE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bayer Hlthcare | ASTEPRO ALLERGY | azelastine hydrochloride | SPRAY, METERED;NASAL | 213872-001 | Jun 17, 2021 | OTC | Yes | Yes | 8,518,919 | ⤷ Subscribe | ⤷ Subscribe | ||||
Bayer Hlthcare | LEVITRA | vardenafil hydrochloride | TABLET;ORAL | 021400-003 | Aug 19, 2003 | DISCN | Yes | No | 8,273,876 | ⤷ Subscribe | ⤷ Subscribe | ||||
Bayer Hlthcare | VITRAKVI | larotrectinib sulfate | CAPSULE;ORAL | 210861-001 | Nov 26, 2018 | RX | Yes | No | 10,774,085 | ⤷ Subscribe | ⤷ Subscribe | ||||
Bayer Hlthcare | CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER | ciprofloxacin | INJECTABLE;INJECTION | 019857-001 | Dec 26, 1990 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | |||||
Bayer Hlthcare | XOFIGO | radium ra-223 dichloride | SOLUTION;INTRAVENOUS | 203971-001 | May 15, 2013 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | |||||
Bayer Hlthcare | ADEMPAS | riociguat | TABLET;ORAL | 204819-001 | Oct 8, 2013 | AB | RX | Yes | No | 7,173,037 | ⤷ Subscribe | Y | Y | ⤷ Subscribe | |
Bayer Hlthcare | STIVARGA | regorafenib | TABLET;ORAL | 203085-001 | Sep 27, 2012 | RX | Yes | Yes | 9,957,232 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for BAYER HLTHCARE
Paragraph IV (Patent) Challenges for BAYER HLTHCARE drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 3 mg; 2 mg/2 mg; 2 mg/3 mg; 1 mg | ➤ Subscribe | 2010-10-22 |
➤ Subscribe | Tablets | 25 mg, 50 mg and 100 mg | ➤ Subscribe | 2005-03-22 |
➤ Subscribe | Tablets | 40 mg | ➤ Subscribe | 2016-09-27 |
➤ Subscribe | Oral Suspension | 250 mg/5 mL and 500 mg/ 5 mL | ➤ Subscribe | 2009-10-16 |
➤ Subscribe | Tablets | 3 mg/0.03 mg | ➤ Subscribe | 2005-01-07 |
➤ Subscribe | Orally Disintegrating Tablets | 10 mg | ➤ Subscribe | 2011-12-22 |
➤ Subscribe | Tablets | 0.5 mg/1 mg | ➤ Subscribe | 2007-12-26 |
➤ Subscribe | Tablets | 3 mg/0.02 mg/0.451 mg and 0.451 mg | ➤ Subscribe | 2011-11-21 |
➤ Subscribe | Tablets | 20 mg | ➤ Subscribe | 2009-03-05 |
➤ Subscribe | Tablets | 2.5 mg | ➤ Subscribe | 2009-09-04 |
➤ Subscribe | Tablets | 200 mg | ➤ Subscribe | 2014-02-28 |
➤ Subscribe | Tablets | 3 mg/0.03 mg/0.451 mg and 0.451 mg | ➤ Subscribe | 2012-09-28 |
➤ Subscribe | Transdermal System | 0.05 mg/day and 0.1 mg/day | ➤ Subscribe | 2005-09-12 |
➤ Subscribe | Tablets | 3 mg/0.02 mg | ➤ Subscribe | 2006-09-29 |
➤ Subscribe | Injection | 1.6 mg/mL | ➤ Subscribe | 2014-02-07 |
➤ Subscribe | Tablets | 0.5 mg, 1 mg,1.5 mg, 2 mg and2.5 mg | ➤ Subscribe | 2017-10-10 |
➤ Subscribe | Tablets | 0.25 mg/0.5 mg | ➤ Subscribe | 2015-01-08 |
➤ Subscribe | Tablets | 3 mg/0.02 mg/0.451 mg and 0.451 mg | ➤ Subscribe | 2012-11-13 |
➤ Subscribe | Tablets | 5 mg ad 10 mg | ➤ Subscribe | 2009-07-10 |
International Patents for BAYER HLTHCARE Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Portugal | 1740163 | ⤷ Subscribe |
Guatemala | 200300101 | ⤷ Subscribe |
Lithuania | 2725028 | ⤷ Subscribe |
El Salvador | 2006002090 | ⤷ Subscribe |
Cyprus | 1111065 | ⤷ Subscribe |
European Patent Office | 2958914 | ⤷ Subscribe |
South Korea | 20060134168 | ⤷ Subscribe |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for BAYER HLTHCARE Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1140212 | 2014/033 | Ireland | ⤷ Subscribe | PRODUCT NAME: RADIUM-223 AND SALTS THEREOF; REGISTRATION NO/DATE: EU/1/13/873 20131113 |
3632448 | 22C1031 | France | ⤷ Subscribe | PRODUCT NAME: DROSPIRENONE; NAT. REGISTRATION NO/DATE: NL49691 20191121; FIRST REGISTRATION: DK - 61678 20191016 |
1453521 | C 2015 029 | Romania | ⤷ Subscribe | PRODUCT NAME: LEVONORGESTREL SI ETINILESTRADIOL; NATIONAL AUTHORISATION NUMBER: RO 7793/2015/001; DATE OF NATIONAL AUTHORISATION: 20150612; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): SK. 17/0017/15-S; DATE OF FIRST AUTHORISATION IN EEA: 20150129 |
1506193 | C300659 | Netherlands | ⤷ Subscribe | PRODUCT NAME: RIOCIGUAT, DESGEW ENST IN DE; REGISTRATION NO/DATE: EU/1/13/907 20140327 |
0402407 | 97C0005 | Belgium | ⤷ Subscribe | PRODUCT NAME: ESTRADIOL HEMIHYDRAAT; NAT. REGISTRATION NO/DATE: 298 IS 190 F 15 19960806; FIRST REGISTRATION: GB PL/0053/0241 19950711 |
1453521 | 39/2015 | Austria | ⤷ Subscribe | PRODUCT NAME: ETHINYLESTRADIOL UND EINE KOMBINATION VON LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 136021 20150224; FIRST REGISTRATION: SK 17/0017/15-S 20150211 |
1429780 | 132013902137451 | Italy | ⤷ Subscribe | PRODUCT NAME: CIPROFLOXACINA E DESAMETASONE(CILODEX); AUTHORISATION NUMBER(S) AND DATE(S): 48976, 20120810;041182015/M, 20121106 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.